Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

Jianyong Liu,Qing-Li He,Jianya Zhou,Roshan Chikarmane,Glenn Hauk,Archana Rachakonda,Ajay M Vaghasia,Nicole Castagna,Ruchama C Steinberg,Minh-Tam Pham,Nicole M Anders,Teresia M Wanjiku,Philipp Nuhn,Joong Sup Shim,Hugh Giovinazzo,David M Esopi,Kunhwa Kim,Jonathan Coulter,Rulin Wang,Jianying Zhou,Michelle A Rudek,James M Berger,Jun O Liu,William G Nelson,Srinivasan Yegnasubramanian

DOI: https://doi.org/10.1101/2024.05.19.594134

2024-05-21

Abstract:While nucleoside DNA methyltransferase inhibitors (DNMTi) such as decitabine and azacitidine are effective in treating myelodysplatic syndrome (MDS)/leukemia, they have had limited utility for the majority of other cancers. Through a chemical library screen, we identified that triptolide, a diterpenoid epoxide from Tripterygium wilfordii, or analogs significantly augmented the epigenetic and anti-cancer effects of decitabine in vitro and in vivo. These effects were attributable to inhibition of DCTPP1-mediated cleavage of 5-aza-deoxycytidine triphosphate, the convergent activated metabolite of nucleoside DNMTi, leading to enhanced drug incorporation into genomic DNA, increased DNMT degradation, enhanced global DNA demethylation and associated transcriptional reprogramming. We show that high DCTPP1 expression was associated with cell-intrinsic resistance to nucleoside DNMTi, and that triptolide and its analogs could overcome this resistance.

Cancer Biology

What problem does this paper attempt to address?

The problem this paper attempts to address is: how to enhance the efficacy of nucleotide DNA methyltransferase inhibitors (DNMTi) such as Decitabine in the treatment of various cancers. Although these drugs have shown some efficacy in treating myelodysplastic syndromes (MDS) and certain acute myeloid leukemias (AML), their effectiveness is limited for most other types of cancer. Through chemical library screening, researchers found that Triptolide or its analogs can significantly enhance the epigenetic and anticancer effects of Decitabine. Specifically, Triptolide increases the incorporation of the drug into genomic DNA by inhibiting DCTPP1-mediated pyrophosphohydrolysis of 5-aza-2'-deoxycytidine triphosphate (5-aza-dCTP), thereby enhancing DNA methyltransferase degradation, global DNA demethylation, and associated transcriptional reprogramming. The study also found that high expression of DCTPP1 is associated with intrinsic resistance of cells to nucleotide DNMTi, and Triptolide and its analogs can overcome this resistance. Therefore, this study aims to explore the potential of combining Triptolide with nucleotide DNMTi to overcome cancer cell resistance to these drugs and improve therapeutic outcomes.

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance

Triptolide Inhibits Transcription Factor Nf-Kappab and Induces Apoptosis of Multiple Myeloma Cells

Triptolide Enhances the Sensitivity of Multiple Myeloma Cells to Dexamethasone Via Micrornas.

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.

Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.

Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

Triptolide impairs genome integrity by directly blocking the enzymatic activity of DNA-PKcs in human cells

3093 – DHODH INHIBITION SYNERGIZES WITH DNA-DEMETHYLATING AGENTS IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma

Targeting DNA methyltransferases for cancer therapy

Triptolide induces caspase-dependent cell death mediated via the mitochondrial pathway in leukemic cells

Regulation of triptolide on histone demethylase in multiple myeloma U266 cells

Triptolide Induces Mitochondrial Apoptosis Through Modulating Dual Specificity Phosphatase 1/Mitogen-Activated Protein Kinases Cascade in Osteosarcoma Cells

Triptolide Alters Histone H3K9 and H3K27 Methylation State and Induces G0/G1 Arrest and Caspase-Dependent Apoptosis in Multiple Myeloma in Vitro.

Triptolide Shows High Sensitivity and Low Toxicity Against Acute Myeloid Leukemia Cell Lines Through Inhibiting WSTF-RNAPII Complex

Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models

Triptolide Enhances Chemotherapeutic Efficacy of Antitumor Drugs in Non-Small-cell Lung Cancer Cells by Inhibiting Nrf2-ARE Activity